Avanzanite Biosciences Partner Agios Announces PYRUKYND (mitapivat) Approval in the European Union for Adults with Thalassaemia
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts...